Q1 EPS Forecast for Halozyme Therapeutics Lowered by Analyst

Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) - Research analysts at Zacks Research dropped their Q1 2026 earnings estimates for shares of Halozyme Therapeutics in a research report issued on Thursday, June 26th. Zacks Research analyst R. Department now anticipates that the biopharmaceutical company will earn $1.02 per share for the quarter, down from their previous estimate of $1.28. The consensus estimate for Halozyme Therapeutics' current full-year earnings is $4.73 per share. Zacks Research also issued estimates for Halozyme Therapeutics' Q2 2026 earnings at $1.21 EPS, Q3 2026 earnings at $1.46 EPS, Q4 2026 earnings at $1.68 EPS, FY2026 earnings at $5.38 EPS, Q1 2027 earnings at $1.19 EPS and FY2027 earnings at $5.94 EPS.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.98 by $0.13. Halozyme Therapeutics had a net margin of 44.76% and a return on equity of 136.91%. The company had revenue of $264.86 million for the quarter, compared to analysts' expectations of $231.21 million. During the same quarter last year, the company posted $0.79 earnings per share. The firm's quarterly revenue was up 35.2% on a year-over-year basis.

HALO has been the subject of a number of other reports. Leerink Partnrs downgraded Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a research note on Tuesday, May 13th. Benchmark downgraded shares of Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Wednesday, May 7th. HC Wainwright reaffirmed a "buy" rating and set a $72.00 target price on shares of Halozyme Therapeutics in a report on Thursday, May 29th. JPMorgan Chase & Co. lifted their price target on shares of Halozyme Therapeutics from $55.00 to $58.00 and gave the stock a "neutral" rating in a research note on Monday, April 21st. Finally, Wells Fargo & Company boosted their price objective on shares of Halozyme Therapeutics from $60.00 to $65.00 and gave the company an "equal weight" rating in a research report on Wednesday, May 7th. Two research analysts have rated the stock with a sell rating, six have given a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, Halozyme Therapeutics presently has a consensus rating of "Hold" and a consensus target price of $61.90.

Halozyme Therapeutics Stock Performance

Halozyme Therapeutics stock traded up $0.21 during mid-day trading on Monday, reaching $54.05. 868,065 shares of the stock traded hands, compared to its average volume of 2,018,866. Halozyme Therapeutics has a 12-month low of $42.01 and a 12-month high of $70.50. The business's 50-day moving average is $55.72 and its 200-day moving average is $56.49. The company has a debt-to-equity ratio of 3.13, a current ratio of 8.39 and a quick ratio of 7.30. The stock has a market capitalization of $6.66 billion, a PE ratio of 14.38, a price-to-earnings-growth ratio of 0.35 and a beta of 1.15.

Insiders Place Their Bets

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 4,497 shares of the stock in a transaction on Monday, April 28th. The stock was sold at an average price of $60.37, for a total value of $271,483.89. Following the completion of the sale, the director owned 28,611 shares in the company, valued at approximately $1,727,246.07. This represents a 13.58% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Helen Torley sold 20,000 shares of the firm's stock in a transaction dated Tuesday, June 24th. The shares were sold at an average price of $53.73, for a total value of $1,074,600.00. Following the sale, the chief executive officer directly owned 733,719 shares in the company, valued at approximately $39,422,721.87. This represents a 2.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 44,497 shares of company stock worth $2,405,284. 2.40% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Halozyme Therapeutics

Hedge funds have recently modified their holdings of the stock. Norges Bank purchased a new position in Halozyme Therapeutics during the fourth quarter valued at $60,054,000. Capital World Investors purchased a new position in shares of Halozyme Therapeutics during the fourth quarter valued at about $35,773,000. Arrowstreet Capital Limited Partnership grew its position in shares of Halozyme Therapeutics by 141.3% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 992,887 shares of the biopharmaceutical company's stock valued at $47,470,000 after purchasing an additional 581,475 shares in the last quarter. Caisse DE Depot ET Placement DU Quebec increased its holdings in shares of Halozyme Therapeutics by 154.5% in the first quarter. Caisse DE Depot ET Placement DU Quebec now owns 910,169 shares of the biopharmaceutical company's stock worth $58,078,000 after purchasing an additional 552,590 shares during the last quarter. Finally, D. E. Shaw & Co. Inc. lifted its position in shares of Halozyme Therapeutics by 171.2% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 831,414 shares of the biopharmaceutical company's stock worth $39,750,000 after buying an additional 524,802 shares in the last quarter. Hedge funds and other institutional investors own 97.79% of the company's stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.